ArticleInternational journal of nanomedicine2010
Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery.
Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.Journal of cancer research and clinical oncology · 2026Review
- Engineered cell-biomimetic nanosystems for anti-inflammatory therapy: Targeting, neutralization and immunomodulation.Acta pharmaceutica Sinica. B · 2026Review
- Protocol for MR1-ligand cross-linking to discover metabolite antigens by proteomics.STAR protocols · 2026Article
- Review
- Chemical Surface Modification Tolerance of Primary and Immortalized Macrophages and Stem Cells.Chembiochem : a European journal of chemical biology · 2025Article
- Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy.Asian journal of pharmaceutical sciences · 2025Review
- MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens.Cell reports methods · 2025Article
- Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases.Pharmaceutics · 2024Review
- Cell-mediated nanoparticle delivery systems: towards precision nanomedicine.Drug delivery and translational research · 2024Review
- Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.International journal of nanomedicine · 2024Review
- Cell Surface Engineering Tools for Programming Living Assemblies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Biomimetic Systems Involving Macrophages and Their Potential for Targeted Drug Delivery.Biomimetics (Basel, Switzerland) · 2023Review
- Nanotoxicity of multifunctional stoichiometric cobalt oxide nanoparticles (SCoONPs) with repercussions toward apoptosis, necrosis, and cancer necrosis factor (TNF-α) at nano-biointerfaces.Toxicology research · 2023Review
- Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression.Materials today. Bio · 2023Review
- Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.Frontiers in bioengineering and biotechnology · 2023Review
- From Bench to Cell: A Roadmap for Assessing the Bioorthogonal "Click" Reactivity of Magnetic Nanoparticles for Cell Surface Engineering.Bioconjugate chemistry · 2022Article
- Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers.Frontiers in immunology · 2022Review
- Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.Pharmaceutics · 2021Review
- Delivery of Cinnamic Aldehyde Antioxidant Response Activating nanoParticles (ARAPas) for Vascular Applications.Antioxidants (Basel, Switzerland) · 2021Article
- Engineering MacrophagesFrontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumors frequently contain hypoxic regions that result from a shortage of oxygen due to poorly organized tumor vasculature. Cancer cells in these areas are resistant to radiation- and chemotherapy, limiting the treatment efficacy. Macrophages have inherent hypoxia-targeting ability and hold great advantages for targeted delivery of anticancer therapeutics to cancer cells in hypoxic areas. However, most anticancer drugs cannot be directly loaded into macrophages because of their toxicity. In this work, we designed a novel drug delivery vehicle by hybridizing macrophages with nanoparticles through cell surface modification. Nanoparticles immobilized on the cell surface provide numerous new sites for anticancer drug loading, hence potentially minimizing the toxic effect of anticancer drugs on the viability and hypoxia-targeting ability of the macrophage vehicles. In particular, quantum dots and 5-(aminoacetamido) fluorescein-labeled polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized polyethylene glycol, were immobilized to the sodium periodate-treated surface of RAW264.7 macrophages through a transient Schiff base linkage. Further, a reducing agent, sodium cyanoborohydride, was applied to reduce Schiff bases to stable secondary amine linkages. The distribution of nanoparticles on the cell surface was confirmed by fluorescence imaging, and it was found to be dependent on the stability of the linkages coupling nanoparticles to the cell surface.
Indexed as
Identifiers
20161985PMC2819902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.